<p>Taysha Gene Therapies（纳斯达克代码：TSHA - 获取免费报告）预计将在 2026 年 5 月 6 日星期三市场开盘前发布其 2026 年第一季度财报。分析师预计 Taysha Gene Therapies 将发布每股收益（$0.10）和季度收入为 75.60 万美元。感兴趣的人员被鼓励访问公司即将发布的 2026 年第一季度财报概览页面，以获取关于定于 2026 年 5 月 6 日东部时间上午 8:30 的电话会议的最新详情。</p>
<ul>
<li>Neurogene 股票暴跌 44%：这家生物技术公司还有希望吗？</li>
</ul>
<p>Taysha Gene Therapies（纳斯达克代码：TSHA - 获取免费报告）上一次发布季度财报是在 3 月 19 日星期四。该公司报告的季度每股收益为（$0.08），超出分析师的共识预期（$0.11）$0.03。该公司的季度收入为 549 万美元，而共识预期为 189 万美元。分析师平均预计 Taysha Gene Therapies 在当前财年和下一个财年将发布每股收益为$0。</p>
<p>获取 <strong>Taysha Gene Therapies</strong> 的提醒：</p>
<h2>Taysha Gene Therapies 股票下跌 0.9%</h2>
<p>TSHA 在星期五开盘价为$6.33。该公司的债务与股本比率为 0.20，流动比率为 12.23，速动比率为 12.23。公司的 50 日移动平均线为$4.95，200 日移动平均线为$4.89。Taysha Gene Therapies 的 52 周低点为$1.85，52 周高点为$6.76。该公司的市值为 18.2 亿美元，市盈率为-18.62，贝塔值为 1.25。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>3 只小盘股适合你的秋季购物清单</li>
</ul>
<p>多家研究公司最近对 TSHA 进行了评估。华尔街 Zen 在 3 月 21 日星期六的研究报告中将 Taysha Gene Therapies 的评级从 “卖出” 上调至 “持有”。Needham &amp; Company LLC 在 3 月 19 日星期四的研究报告中将 Taysha Gene Therapies 的目标价从$10.00 上调至$12.00，并给予该公司 “买入” 评级。Chardan Capital 在 3 月 19 日星期四的研究报告中重申了 “买入” 评级，并设定了$12.00 的目标价。Weiss Ratings 在 3 月 27 日星期五的研究报告中重申了对 Taysha Gene Therapies 的 “卖出（d-）” 评级。最后，Truist Financial 在 3 月 25 日星期三的研究报告中将 Taysha Gene Therapies 的评级上调至 “强力买入”。两位投资分析师给予该股票 “强力买入” 评级，十位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价为$11.64。</p>
<p><strong>阅读我们关于 Taysha Gene Therapies 的最新股票分析</strong></p>
<h2>内部买卖情况</h2>
<p>在其他 Taysha Gene Therapies 的新闻中，内部人士 Sukumar Nagendran 在 4 月 10 日星期五出售了 200,000 股 Taysha Gene Therapies 的股票。股票以平均价格$4.46 出售，总价值为$892,000.00。出售后，该内部人士持有公司 1,136,410 股股票，价值约为$5,068,388.60。此次交易使其持股减少了 14.97%。该交易已在与 SEC 的法律文件中披露，可以通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。公司内部人士持有公司股票的 3.78%。</p>
<h2>Taysha Gene Therapies 的机构交易</h2>
<p>对该股票的对冲基金最近增加或减少了其持股。Marex Group plc 在第二季度购买了 Taysha Gene Therapies 的新股份，价值约$29,000。E Fund Management Co. Ltd.在第二季度购买了 Taysha Gene Therapies 的新股份，价值约$31,000。Tower Research Capital LLC TRC 在第二季度将其在 Taysha Gene Therapies 的持股增加了 156.5%。Tower Research Capital LLC TRC 现在拥有 17,606 股公司股票，价值$41,000，此前在此期间又购买了 10,742 股。BNP Paribas Financial Markets 在第二季度将其在 Taysha Gene Therapies 的持股增加了 51.9%。BNP Paribas Financial Markets 现在拥有 18,591 股公司股票，价值$43,000，此前在此期间又购买了 6,350 股。最后，Caitong International Asset Management Co. Ltd 在第四季度将其在 Taysha Gene Therapies 的持股增加了 143.8%。Caitong International Asset Management Co. Ltd 现在拥有 7,811 股公司股票，价值$43,000，此前在此期间又购买了 4,607 股。机构投资者持有公司 77.70% 的股票。</p>
<h2>Taysha Gene Therapies 公司简介</h2>
<p>（获取免费报告）</p>
<p>Taysha Gene Therapies, Inc（纳斯达克：TSHA）是一家临床阶段的生物技术公司，专注于开发针对中枢神经系统罕见单基因疾病的基因疗法。该公司使用专有的腺病毒相关病毒（AAV）载体平台，设计新型衣壳和调控元件，以优化治疗基因的递送和表达。其产品管线包括针对 GM2 神经节苷脂症（Tay-Sachs 和 Sandhoff 病）的 TSHA-102，针对 GM1 神经节苷脂症的 TSHA-101，以及针对芳香 L-氨基酸脱羧酶（AADC）缺乏症的 TSHA-103，以及针对其他危及生命的儿科中枢神经系统疾病的早期候选药物。</p>
<p>Taysha Gene Therapies 成立于 2019 年，总部位于德克萨斯州达拉斯，于 2021 年 5 月完成首次公开募股。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Taysha Gene Therapies</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Taysha Gene Therapies 吗？</h2>
<p>在你考虑 Taysha Gene Therapies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Taysha Gene Therapies 并不在名单上。</p>
<p>虽然 Taysha Gene Therapies 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TSHA

动态生物技术与基因组 ETF - Invesco

基因改革 ETF - ARK

<p>Taysha Gene Therapies（纳斯达克代码：TSHA）将于 5 月 6 日发布 2026 年第一季度财报，分析师预测每股亏损 0.10 美元，收入为 75.6 万美元。该公司此前报告了 2025 年第一季度每股亏损 0.08 美元，超出预期。TSHA 的股票目前下跌 0.9%，市值为 18.2 亿美元。最近的分析师评级包括买入和持有的混合推荐，平均目标价为 11.64 美元。内部交易活动显示一位高管进行了大额出售，而机构持股比例为 77.70%</p>

<p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Taysha Gene Therapies to post earnings of ($0.10) per share and revenue of $0.7560 million for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:30 AM ET.</p>
<div class="lb-trans"><p>Taysha Gene Therapies（纳斯达克代码：TSHA - 获取免费报告）预计将在 2026 年 5 月 6 日星期三市场开盘前发布其 2026 年第一季度财报。分析师预计 Taysha Gene Therapies 将发布每股收益（$0.10）和季度收入为 75.60 万美元。感兴趣的人员被鼓励访问公司即将发布的 2026 年第一季度财报概览页面，以获取关于定于 2026 年 5 月 6 日东部时间上午 8:30 的电话会议的最新详情。</p>
</div><ul>
<li>Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?&#34;</li>
</ul>
<div class="lb-trans"><ul>
<li>Neurogene 股票暴跌 44%：这家生物技术公司还有希望吗？</li>
</ul>
</div><p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to the consensus estimate of $1.89 million. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Taysha Gene Therapies（纳斯达克代码：TSHA - 获取免费报告）上一次发布季度财报是在 3 月 19 日星期四。该公司报告的季度每股收益为（$0.08），超出分析师的共识预期（$0.11）$0.03。该公司的季度收入为 549 万美元，而共识预期为 189 万美元。分析师平均预计 Taysha Gene Therapies 在当前财年和下一个财年将发布每股收益为$0。</p>
</div><p>Get <strong>Taysha Gene Therapies</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Taysha Gene Therapies</strong> 的提醒：</p>
</div><h2>Taysha Gene Therapies Stock Down 0.9%</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 股票下跌 0.9%</h2>
</div><p>TSHA opened at $6.33 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 12.23 and a quick ratio of 12.23. The company's 50-day moving average is $4.95 and its 200 day moving average is $4.89. Taysha Gene Therapies has a fifty-two week low of $1.85 and a fifty-two week high of $6.76. The firm has a market capitalization of $1.82 billion, a P/E ratio of -18.62 and a beta of 1.25.</p>
<div class="lb-trans"><p>TSHA 在星期五开盘价为$6.33。该公司的债务与股本比率为 0.20，流动比率为 12.23，速动比率为 12.23。公司的 50 日移动平均线为$4.95，200 日移动平均线为$4.89。Taysha Gene Therapies 的 52 周低点为$1.85，52 周高点为$6.76。该公司的市值为 18.2 亿美元，市盈率为-18.62，贝塔值为 1.25。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>3 Small-Cap Stocks For Your Fall Shopping List</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小盘股适合你的秋季购物清单</li>
</ul>
</div><p>A number of research firms recently weighed in on TSHA. Wall Street Zen raised shares of Taysha Gene Therapies from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, March 21st. Needham &amp; Company LLC raised their price target on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, March 19th. Chardan Capital reissued a &#34;buy&#34; rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th. Finally, Truist Financial raised shares of Taysha Gene Therapies to a &#34;strong-buy&#34; rating in a research report on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Buy&#34; and an average target price of $11.64.</p>
<div class="lb-trans"><p>多家研究公司最近对 TSHA 进行了评估。华尔街 Zen 在 3 月 21 日星期六的研究报告中将 Taysha Gene Therapies 的评级从 “卖出” 上调至 “持有”。Needham &amp; Company LLC 在 3 月 19 日星期四的研究报告中将 Taysha Gene Therapies 的目标价从$10.00 上调至$12.00，并给予该公司 “买入” 评级。Chardan Capital 在 3 月 19 日星期四的研究报告中重申了 “买入” 评级，并设定了$12.00 的目标价。Weiss Ratings 在 3 月 27 日星期五的研究报告中重申了对 Taysha Gene Therapies 的 “卖出（d-）” 评级。最后，Truist Financial 在 3 月 25 日星期三的研究报告中将 Taysha Gene Therapies 的评级上调至 “强力买入”。两位投资分析师给予该股票 “强力买入” 评级，十位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价为$11.64。</p>
</div><p><strong>Read Our Latest Stock Analysis on Taysha Gene Therapies</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Taysha Gene Therapies 的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖情况</h2>
</div><p>In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $4.46, for a total value of $892,000.00. Following the sale, the insider owned 1,136,410 shares of the company's stock, valued at approximately $5,068,388.60. The trade was a 14.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.78% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Taysha Gene Therapies 的新闻中，内部人士 Sukumar Nagendran 在 4 月 10 日星期五出售了 200,000 股 Taysha Gene Therapies 的股票。股票以平均价格$4.46 出售，总价值为$892,000.00。出售后，该内部人士持有公司 1,136,410 股股票，价值约为$5,068,388.60。此次交易使其持股减少了 14.97%。该交易已在与 SEC 的法律文件中披露，可以通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。公司内部人士持有公司股票的 3.78%。</p>
</div><h2>Institutional Trading of Taysha Gene Therapies</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 的机构交易</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the stock. Marex Group plc bought a new stake in Taysha Gene Therapies in the second quarter worth about $29,000. E Fund Management Co. Ltd. bought a new stake in Taysha Gene Therapies in the second quarter worth about $31,000. Tower Research Capital LLC TRC raised its position in Taysha Gene Therapies by 156.5% in the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company's stock worth $41,000 after acquiring an additional 10,742 shares during the period. BNP Paribas Financial Markets raised its position in Taysha Gene Therapies by 51.9% in the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company's stock worth $43,000 after acquiring an additional 6,350 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its position in Taysha Gene Therapies by 143.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company's stock worth $43,000 after acquiring an additional 4,607 shares during the period. Institutional investors own 77.70% of the company's stock.</p>
<div class="lb-trans"><p>对该股票的对冲基金最近增加或减少了其持股。Marex Group plc 在第二季度购买了 Taysha Gene Therapies 的新股份，价值约$29,000。E Fund Management Co. Ltd.在第二季度购买了 Taysha Gene Therapies 的新股份，价值约$31,000。Tower Research Capital LLC TRC 在第二季度将其在 Taysha Gene Therapies 的持股增加了 156.5%。Tower Research Capital LLC TRC 现在拥有 17,606 股公司股票，价值$41,000，此前在此期间又购买了 10,742 股。BNP Paribas Financial Markets 在第二季度将其在 Taysha Gene Therapies 的持股增加了 51.9%。BNP Paribas Financial Markets 现在拥有 18,591 股公司股票，价值$43,000，此前在此期间又购买了 6,350 股。最后，Caitong International Asset Management Co. Ltd 在第四季度将其在 Taysha Gene Therapies 的持股增加了 143.8%。Caitong International Asset Management Co. Ltd 现在拥有 7,811 股公司股票，价值$43,000，此前在此期间又购买了 4,607 股。机构投资者持有公司 77.70% 的股票。</p>
</div><h2>Taysha Gene Therapies Company Profile</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.</p>
<div class="lb-trans"><p>Taysha Gene Therapies, Inc（纳斯达克：TSHA）是一家临床阶段的生物技术公司，专注于开发针对中枢神经系统罕见单基因疾病的基因疗法。该公司使用专有的腺病毒相关病毒（AAV）载体平台，设计新型衣壳和调控元件，以优化治疗基因的递送和表达。其产品管线包括针对 GM2 神经节苷脂症（Tay-Sachs 和 Sandhoff 病）的 TSHA-102，针对 GM1 神经节苷脂症的 TSHA-101，以及针对芳香 L-氨基酸脱羧酶（AADC）缺乏症的 TSHA-103，以及针对其他危及生命的儿科中枢神经系统疾病的早期候选药物。</p>
</div><p>Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.</p>
<div class="lb-trans"><p>Taysha Gene Therapies 成立于 2019 年，总部位于德克萨斯州达拉斯，于 2021 年 5 月完成首次公开募股。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Taysha Gene Therapies</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Taysha Gene Therapies</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=TSHA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Taysha Gene Therapies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Taysha Gene Therapies 吗？</h2>
</div><p>Before you consider Taysha Gene Therapies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Taysha Gene Therapies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Taysha Gene Therapies 并不在名单上。</p>
</div><p>While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Taysha Gene Therapies 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Taysha Gene Therapies (TSHA) 将在周三公布其财务业绩